Profile data is unavailable for this security.
About the company
Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
- Revenue in EUR (TTM)12.49m
- Net income in EUR-123.83k
- Incorporated2000
- Employees57.00
- LocationIntegragen SAGenopole Campus 1Genavenir 8 5 rue Henri DesbrueresEVRY 91000FranceFRA
- Phone+33 160910900
- Fax+33 160910928
- Websitehttps://integragen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapid Nutrition PLC | 1.82m | -1.45m | 946.00k | 9.00 | 40.47 | 559.55 | -- | 0.5209 | 0.0017 | 0.0017 | 0.0034 | 0.0001 | 1.84 | 3.90 | 3.05 | 201,785.00 | -146.98 | -- | -1,011.07 | -- | 71.47 | -- | -79.74 | -- | 1.07 | -- | 0.7674 | -- | -1.50 | -- | -1,090.33 | -- | -- | -- |
| Theravet SA | -100.00bn | -100.00bn | 1.91m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hybrigenics SA | 0.00 | -69.16k | 3.46m | 17.00 | -- | 0.2465 | -- | -- | -0.0003 | -0.0003 | 0.00 | 0.0361 | 0.00 | -- | -- | -- | -0.7067 | -35.48 | -0.877 | -48.94 | -- | -- | -- | -5,115.72 | -- | -- | 0.1032 | -- | 100.00 | -- | 78.83 | -- | -- | -- |
| IntegraGen SA | 12.49m | -123.83k | 4.00m | 57.00 | -- | 2.06 | 49.13 | 0.3204 | -0.0179 | -0.0179 | 1.88 | 0.2887 | 1.24 | 9.09 | 3.09 | 198,274.60 | -1.23 | -4.20 | -4.00 | -9.43 | 64.75 | 64.10 | -0.9913 | -3.67 | 1.23 | -- | 0.418 | -- | 16.27 | 16.08 | -122.78 | -- | -- | -- |
| Medesis Pharma SA | 0.00 | -2.79m | 5.31m | 10.00 | -- | -- | -- | -- | -0.6324 | -0.6324 | 0.00 | -0.5862 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.14 | -23.17 | -- | -- | -100.00 | -- | -3.87 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -18.65m | 6.05m | 24.00 | -- | 12.88 | -- | -- | -1.68 | -1.68 | 0.00 | 0.0298 | 0.00 | -- | -- | 0.00 | -145.59 | -- | -297.22 | -- | -- | -- | -- | -- | -- | -9.32 | 0.9504 | -- | -- | -- | -25.94 | -- | -- | -- |
| Theranexus SA | 0.00 | -6.83m | 8.53m | 19.00 | -- | 3.84 | -- | -- | -1.09 | -1.09 | 0.00 | 0.2863 | 0.00 | -- | -- | 0.00 | -70.79 | -42.66 | -82.29 | -47.97 | -- | -- | -- | -- | -- | -1,058.68 | 0.6212 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 10.06k | -3.17m | 8.67m | 3.00 | -- | 9.93 | -- | 862.02 | -0.091 | -0.091 | 0.0003 | 0.0125 | 0.0007 | -- | 0.0016 | 3,353.33 | -23.14 | -60.77 | -95.19 | -102.24 | -14,205.07 | -3,548.91 | -31,520.38 | -3,374.13 | -- | -146.53 | 0.8615 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 2.34m | -849.00k | 12.57m | 56.00 | -- | 1.70 | -- | 5.37 | -0.7853 | -0.7853 | 2.15 | 6.70 | 0.1368 | 0.9869 | 2.87 | 41,767.86 | -4.91 | -3.18 | -7.20 | -4.04 | 22.83 | 98.91 | -35.87 | -27.90 | 0.8691 | -16.73 | 0.4472 | -- | 1.48 | 23.72 | 25.13 | -- | 3.57 | -- |
| Ikonisys SA | 538.56k | -2.40m | 15.05m | 11.00 | -- | 0.8235 | -- | 27.94 | -0.2499 | -0.2499 | 0.056 | 1.75 | 0.0246 | 1.14 | 6.20 | 48,960.00 | -10.94 | -- | -12.55 | -- | 2.72 | -- | -444.76 | -- | 0.0818 | -36.79 | 0.1007 | -- | 68.94 | -- | -328.57 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Trusteam Finance SCAas of 29 Dec 2023 | 117.12k | 1.74% |
